Willkommen, schön sind Sie da!
Logo Ex Libris

BRAF Targets in Melanoma

  • E-Book (pdf)
  • 204 Seiten
(0) Erste Bewertung abgeben
Alle Bewertungen ansehen
This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which wi... Weiterlesen
E-Books ganz einfach mit der kostenlosen Ex Libris-Reader-App lesen. Hier erhalten Sie Ihren Download-Link.
CHF 154.90
Download steht sofort bereit
Informationen zu E-Books
E-Books eignen sich auch für mobile Geräte (sehen Sie dazu die Anleitungen).
E-Books von Ex Libris sind mit Adobe DRM kopiergeschützt: Erfahren Sie mehr.
Weitere Informationen finden Sie hier.
Bestellung & Lieferung in eine Filiale möglich


This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

Dr. Ryan J. Sullivan is affiliated with Massachusetts General Hospital and Dana Farber. His research interests are in the development of novel molecular therapeutic agents for Kaposi sarcoma (KS) and malignant melanoma and the translation of promising preclinical findings into early stage clinical trials. He serves as the co-director of the Eugene Michael Egan Melanoma Translational Research Laboratory at Beth Israel Deaconess Medical Center (BIDMC) and is actively investigating promising biomarkers of response and benefit to immunotherapy and molecular targeted therapy for patients with melanoma.


1. Melanoma: Historical Context

Suraj Venna, Sekwon Jang, Michael Atkins

2. Melanoma Pathogenesis

Jennifer A. Lo, David E. Fisher

3. Molecular Diagnostics and Tumor Mutational Analysis

Melissa A. Wilson and Katherine L. Nathanson

4. Clinical Utility of BRAF-targeted therapy in Melanoma

Jeffrey A. Sosman and Douglas B. Johnson

5. The Ethics of Randomized Trials in Oncology

Pallavi Kumar, Ryan J. Sullivan

6. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma

Michael A. Davies

7. Targeting the cell cycle and p53 in combination with BRAF-directed therapy

Dale Han, Keiran SM Smalley

8. Combination BRAF-directed therapy and immunotherapy

Zachary A. Cooper, Zain Ahmed, Jennifer A. Wargo

9. Moving Forward: Making BRAF-Targeted Therapy Better

Keith T Flaherty


Titel: BRAF Targets in Melanoma
Untertitel: Biological Mechanisms, Resistance, and Drug Discovery
EAN: 9781493921430
ISBN: 978-1-4939-2143-0
Digitaler Kopierschutz: Wasserzeichen
Format: E-Book (pdf)
Hersteller: Springer New York
Herausgeber: Humana Press
Genre: Medizin
Anzahl Seiten: 204
Veröffentlichung: 24.11.2014
Jahr: 2014
Dateigrösse: 4.8 MB

Weitere Bände aus der Buchreihe "Cancer Drug Discovery and Development"